Trevi Therapeutics Q4 net loss narrows on lower R&D costs

Trevi Therapeutics

17/03/2026 20:21

Overview

U.S. biopharma firm's Q4 net loss narrowed yr/yr on lower R&D expenses

Company ended 2025 with $188.3 mln in cash and projects runway into 2028

Outlook

Company plans to initiate first Phase 3 trial for IPF-related chronic cough in Q2 2026

Company anticipates cash runway into 2028

Result Drivers

LOWER R&D SPENDING - Q4 R&D expenses fell due to decreased clinical development costs for the Phase 2a RIVER and Phase 2b CORAL trials, which were actively enrolling in the prior year period

HIGHER G&A EXPENSES - Q4 G&A expenses rose due to increased professional fees and personnel-related costs

INCREASED INTEREST INCOME - Other income rose due to higher interest income from larger cash and marketable securities balances

Company press release: ID:nGNX87yCZd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.06
Q4 Net Income
-$8.32 mln
Q4 Income from Operations
-$10.22 mln
Q4 Operating Expenses
$10.22 mln
Q4 Pretax Profit
-$8.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $21.00, about 88.2% above its March 16 closing price of $11.16

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)